세계의 콜라겐 및 젤라틴 시장(-2030년) : 원료(소, 돼지, 해산물), 용도(정형외과, 순환기, 치과, 외과), 최종사용자, 지역별

The global collagen & gelatin market is projected to reach USD 1,671.3 million in 2030 from USD 1,295.5 million in 2025, growing at a CAGR of 5.8% during the forecast period. The rising incidence of diabetes, cancer, and cardiovascular diseases increased the demand for efficient treatment, particularly products with advanced wound care. Collagen dressings are becoming popular because they can rapidly heal wounds and minimize infection risk. Moreover, the hike in surgeries has spurred demand for collagen-based biomaterials for sutures, scaffolds, and implants.

Additionally, the expanding uses of collagen in tissue engineering and regenerative medicine, specifically in developing bioengineered skin, cartilage, and bone, are creating new avenues for therapeutic use.

"The collagen segment held the largest share in the product type market during the forecast period"

In 2024, collagen held the largest market within the collagen & gelatin market by product type. The rising adoption of regenerative medicine, orthopedic implants, and dermatological therapies, where native and type-specific collagen plays a critical role in tissue scaffolding and repair. Further, the innovation of recombinant collagen technology and marine-based sources is pushing the boundaries of application into next-generation areas of cell therapy, 3D printing, and custom medicine, thus solidifying it as one of the key material players in the next-generation approach to healthcare solutions.

"The hospital end user segment is projected to hold the largest market share during the forecast period"

Collagen & gelatin products are mainly consumed by the hospital industry. Hospitals are also the central focal points for healing chronic wounds, burns, diabetes ulcers, and postoperative care, wherein dressings made from collagen find extensive use on account of the well-established efficacy of the product for inducing tissue regrowth and recovery at a faster pace. Moreover, hospitals are always on the edge when using next-generation medical devices, regenerative medicines, orthopedic implants, and drug-delivery systems that heavily utilize collagen-based products.

"Asia Pacific is projected to be the fastest-growing region during the forecast period"

The Asia Pacific collagen & gelatin market is projected to register the highest growth rate during the forecast period, attributed to the rapidly expanding biopharmaceutical manufacturing capabilities and increasing investment in regenerative medicine and advanced drug delivery systems. China, India, South Korea, and Japan are upscaling their priority in R&D on collagen-based scaffolds, cell therapies, and tissue engineering, driven by substantial financing and academia-industry linkages.

Also, an increase in clinical trials and contract manufacturing organizations (CROS and CMOs), which are embracing collagen and gelatin as key substances in drug encapsulation, wound healing formulations, and 3D bioprinting technologies, is another primary driver driving the region's highest growth over the forecast period.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 44%, Tier 2 - 32%, and Tier 3 - 24%
• By Designation: (Managers) - 45%, (CXOs, Directors) - 30%, and (Executives) -25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, ROW - 15%

Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant biotechnologies Ltd (Israel), Collagen Solutions plc (UK), Regenity (US), Medtronic plc (Ireland), and Solventum (US) are some of the key players in the collagen & gelatin market .

The study includes an in-depth competitive analysis of these key players in the collagen & gelatin market , with their company profiles, recent developments, and key market strategies.

Research Coverage:

This report provides a detailed picture of the global collagen & gelatin market. It aims to estimate the size and future growth potential of the market across different segments such as the product type, source, application end user, and region. The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the collagen & gelatin market.

Reasons to buy this report :

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall collagen & gelatin market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

• Analysis of key drivers (growing incidence of diabetes, cancer and chronic diseases, rising demand for advanced wound care products, growing number of surgical procedures, increasing use in tissue engineering and regenerative medicine, and rising application of collagen as drug delivery system), restraints (high manufacturing costs, allergenic & ethical concerns), opportunities (growing adoption of marine & recombinant collagen, expansion of 3D bioprinting for organ and tissue fabrication), and challenges (supply chain vulnerabilities) influencing the growth of the collagen & gelatin market
• Product Development/Innovation: Detailed insights into upcoming technologies and new product launches in the collagen & gelatin market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the collagen & gelatin market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players in the collagen & gelatin market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 GROWTH OPPORTUNITIES FOR PLAYERS IN COLLAGEN & GELATIN MARKET
• 4.2 COLLAGEN & GELATIN MARKET IN NORTH AMERICA, BY SOURCE AND COUNTRY, 2024
• 4.3 COLLAGEN & GELATIN MARKET SHARE, BY SOURCE, 2025 TO 2030
• 4.4 COLLAGEN & GELATIN MARKET, BY END USER, 2024
• 4.5 COLLAGEN & GELATIN MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing incidence of diabetes, cancers, and chronic diseases
    • 5.2.1.2 Increasing use in tissue engineering and regenerative medicine
    • 5.2.1.3 Rising demand for advanced wound care products
    • 5.2.1.4 Growing number of surgical procedures
    • 5.2.1.5 Surge in use of collagen as drug delivery system
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High manufacturing cost
    • 5.2.2.2 Allergenic & ethical concerns
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing adoption of marine & recombinant collagen
    • 5.2.3.2 Expansion of 3D bioprinting for organ and tissue fabrication
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Supply chain vulnerabilities
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 COLLAGEN & GELATIN MARKET: ECOSYSTEM ANALYSIS
  • 5.6.1 PRODUCT PROVIDERS
  • 5.6.2 END USERS
  • 5.6.3 REGULATORY BODIES
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Extraction technologies
    • 5.7.1.2 Hydrolyzation & purification
    • 5.7.1.3 Recombinant production
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 3D scanning & printing
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Encapsulation
• 5.8 REGULATORY LANDSCAPE
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATORY FRAMEWORK
    • 5.8.2.1 North America
    • 5.8.2.2 Europe
    • 5.8.2.3 Asia Pacific
    • 5.8.2.4 Rest of the World
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF SUPPLIERS
  • 5.9.4 BARGAINING POWER OF BUYERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS
  • 5.10.2 BUYING CRITERIA
• 5.11 PATENT ANALYSIS
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 PRICING ANALYSIS
  • 5.13.1 AVERAGE SELLING PRICE TREND OF COLLAGEN AND GELATIN PRODUCTS, BY KEY PLAYERS, 2023-2024
  • 5.13.2 AVERAGE SELLING PRICE TREND OF COLLAGEN AND GELATIN PRODUCTS, BY REGION, 2023-2024
• 5.14 TRADE ANALYSIS
  • 5.14.1 IMPORT DATA FOR HS CODE 350300
  • 5.14.2 EXPORT DATA HS CODE 350300
• 5.15 IMPACT OF AI/GEN AI ON COLLAGEN & GELATIN MARKET
• 5.16 INVESTMENT AND FUNDING SCENARIO

6 COLLAGEN AND GELATIN MARKET, BY PRODUCT TYPE

• 6.1 INTRODUCTION
• 6.2 COLLAGEN
  • 6.2.1 GROWING FOCUS ON REGENERATIVE MEDICINE AND DRUG DELIVERY INNOVATION TO BOOST DEMAND
• 6.3 GELATIN
  • 6.3.1 RISING FOCUS ON SOFT AND HARD GELATIN CAPSULES IN ORAL DELIVERY TO DRIVE MARKET

7 COLLAGEN AND GELATIN MARKET, BY SOURCE

• 7.1 INTRODUCTION
• 7.2 BOVINE SOURCES
  • 7.2.1 INCREASED USE IN TISSUE ENGINEERING APPLICATIONS TO DRIVE MARKET
• 7.3 PORCINE SOURCES
  • 7.3.1 LOW ALLERGIC RESPONSE AND BIOCOMPATIBILITY OF PORCINE COLLAGEN AND GELATIN TO BOOST DEMAND
• 7.4 OTHER SOURCES

8 COLLAGEN MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 ORTHOPEDIC
  • 8.2.1 INCREASING USE OF COLLAGEN IN ORTHOPEDIC SURGERIES TO DRIVE MARKET
• 8.3 WOUND CARE
  • 8.3.1 RISING PREVALENCE OF CHRONIC WOUND CONDITIONS TO BOOST COLLAGEN ADOPTION
• 8.4 DENTAL
  • 8.4.1 RISING INCIDENCE OF ORAL DISORDERS TO DRIVE MARKET
• 8.5 SURGICAL
  • 8.5.1 INCREASING NUMBER OF SURGICAL PROCEDURES GLOBALLY TO BOOST DEMAND FOR COLLAGEN PRODUCTS
• 8.6 CARDIOVASCULAR
  • 8.6.1 GROWING USE OF COLLAGEN PATCHES TO IMPROVE HEART FUNCTION TO SUPPORT MARKET GROWTH
• 8.7 OTHER APPLICATIONS

9 GELATIN MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 ORTHOPEDIC
  • 9.2.1 USE OF GELATIN IN BONE AND CARTILAGE REGENERATION TREATMENT TO DRIVE MARKET
• 9.3 WOUND CARE
  • 9.3.1 APPLICATION OF GELATIN-BASED HYDROGELS IN TREATING BURNS TO DRIVE MARKET
• 9.4 OTHER APPLICATIONS

10 COLLAGEN AND GELATIN MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 SIGNIFICANT USE OF BIOSURGERY PRODUCTS IN HOSPITALS TO DRIVE MARKET
• 10.3 SURGICAL CENTERS
  • 10.3.1 AVAILABILITY OF HIGH-QUALITY AND LOW-COST MEDICAL SERVICES AT SURGICAL CENTERS TO BOOST DEMAND

11 COLLAGEN & GELATIN MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Increasing incidence of periodontitis and burn injuries to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Growing geriatric population and volume of surgeries to boost collagen and gelatin demand
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Increase in healthcare expenditure to boost adoption of collagen and gelatin products
  • 11.3.3 UK
    • 11.3.3.1 High risk of pressure ulcers in diabetic patients to drive market
  • 11.3.4 FRANCE
    • 11.3.4.1 Well-established healthcare sector to provide lucrative opportunities to collagen and gelatin vendors
  • 11.3.5 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Rising elderly population to support market growth
  • 11.4.3 CHINA
    • 11.4.3.1 Significant elderly population with diabetes to push demand for collagen and gelatin products
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing healthcare spending by government to stimulate market growth
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 INCREASING NUMBER OF DIABETIC PATIENTS TO RISE DEMAND FOR COLLAGEN AND GELATIN PRODUCTS
  • 11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 GROWING FOCUS ON HEALTHCARE INFRASTRUCTURE IMPROVEMENT TO DRIVE MARKET
  • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COLLAGEN & GELATIN MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Source footprint
    • 12.5.5.4 Application footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
      • 13.1.1.3.2 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 SMITH+NEPHEW
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 MnM view
      • 13.1.2.3.1 Key strengths
      • 13.1.2.3.2 Strategic choices
      • 13.1.2.3.3 Weaknesses and competitive threats
  • 13.1.3 DSM-FIRMENICH
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths/Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses/Competitive threats
  • 13.1.4 NITTA GELATIN INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 MnM view
      • 13.1.4.3.1 Key strengths
      • 13.1.4.3.2 Strategic choices
      • 13.1.4.3.3 Weaknesses and competitive threats
  • 13.1.5 TESSENDERLO GROUP
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
      • 13.1.5.3.2 Other developments
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths/Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses/Competitive threats
  • 13.1.6 SOLVENTUM
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Other developments
  • 13.1.7 MEDTRONIC PLC
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
  • 13.1.8 COLLPLANT BIOTECHNOLOGIES LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches
      • 13.1.8.3.2 Deals
  • 13.1.9 ZIMVIE INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 JELLAGEN
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Other developments
  • 13.1.11 COLLAGEN SOLUTIONS PLC
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
  • 13.1.12 REGENITY
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 SYMATESE LABS
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 GELITA AG
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 BICO
  • 13.2.2 MATRICEL GMBH
  • 13.2.3 DARLING INGREDIENTS
  • 13.2.4 WEISHARDT
  • 13.2.5 HYFINE GELATIN CO., LTD.
  • 13.2.6 GEISTLICH PHARMA AG
  • 13.2.7 SYNERHEAL PHARMACEUTICALS
  • 13.2.8 BIOREGEN TECHNOLOGIES
  • 13.2.9 MERIL LIFE SCIENCES PVT. LTD.
  • 13.2.10 MEDSKIN SUWELACK
  • 13.2.11 COLOGENESIS HEALTHCARE PVT LTD
  • 13.2.12 DERMARITE INDUSTRIES, LLC
  • 13.2.13 EUCARE PHARMACEUTICALS PRIVATE LIMITED

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS